

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Hong DS, Fakih MG, Strickler JH, et al. KRAS^{G12C} inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383:1207-17. DOI: 10.1056/NEJMoa1917239

Supplementary Appendix

KRAS^{G12C} Inhibition in Advanced Solid Tumors

David S. Hong et al.

Table of Contents

Table S1. Full List of Baseline Demographics 2

Table S2. Full List of Treatment-Emergent Adverse Events by Preferred Term 5

Table S3. Full List of Treatment-Related Adverse Events by System Organ Class, Preferred Term, and Grade 24

Figure S1. Co-crystal Structure of GDP-KRAS^{G12C} Bound by Sotorasib 55

Figure S2. Patient Disposition 56

Figure S3. Pharmacokinetics of Sotorasib 57

Figure S4. CT Scans of Two Patients With NSCLC 58

Figure S5. Efficacy of Sotorasib in Patients With Colorectal Cancer 59

Figure S6. Efficacy of Sotorasib in Patients With Other Tumor Types 63

Supplementary Tables

Table S1. Full List of Baseline Demographics

	Phase 1 Any tumor 180 mg QD Fasted (N = 6)	Phase 1 Any tumor 360 mg QD Fasted (N = 27)	Phase 1 Any tumor 720 mg QD Fasted (N = 11)	Phase 1 Any tumor 960 mg QD Fasted (N = 85)	Phase 1 Any tumor Mono Total (N = 129)
Sex - n (%)					
Male	3 (50.0)	7 (25.9)	5 (45.5)	48 (56.5)	63 (48.8)
Female	3 (50.0)	20 (74.1)	6 (54.5)	37 (43.5)	66 (51.2)
Ethnicity - n (%)					
Hispanic or Latino	0 (0.0)	1 (3.7)	1 (9.1)	1 (1.2)	3 (2.3)
Not Hispanic or Latino	5 (83.3)	23 (85.2)	10 (90.9)	79 (92.9)	117 (90.7)
Missing	1 (16.7)	3 (11.1)	0 (0.0)	5 (5.9)	9 (7.0)
Race - n (%)					
American Indian or Alaska Native	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asian	0 (0.0)	1 (3.7)	0 (0.0)	15 (17.6)	16 (12.4)
Black or African American	0 (0.0)	1 (3.7)	1 (9.1)	4 (4.7)	6 (4.7)
Native Hawaiian or Other Pacific Islander	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
White	6 (100.0)	22 (81.5)	9 (81.8)	61 (71.8)	98 (76.0)
Multiple	0 (0.0)	2 (7.4)	0 (0.0)	0 (0.0)	2 (1.6)
Other	0 (0.0)	1 (3.7)	1 (9.1)	5 (5.9)	7 (5.4)
Age (years)					
n	6	27	11	85	129
Mean	61.0	59.0	62.9	63.2	62.2
SD	7.6	11.8	10.7	9.4	10.0
Median	60.0	60.0	67.0	64.0	62.0
Q1, Q3	55.0, 62.0	50.0, 68.0	55.0, 72.0	57.0, 71.0	56.0, 70.0
Min, Max	54, 75	33, 78	40, 76	37, 83	33, 83

	Phase 1 Any tumor 180 mg QD Fasted (N = 6)	Phase 1 Any tumor 360 mg QD Fasted (N = 27)	Phase 1 Any tumor 720 mg QD Fasted (N = 11)	Phase 1 Any tumor 960 mg QD Fasted (N = 85)	Phase 1 Any tumor Mono Total (N = 129)
Age group - n (%)					
18 - 64 years	5 (83.3)	17 (63.0)	5 (45.5)	43 (50.6)	70 (54.3)
65 - 74 years	0 (0.0)	7 (25.9)	5 (45.5)	34 (40.0)	46 (35.7)
75 - 84 years	1 (16.7)	3 (11.1)	1 (9.1)	8 (9.4)	13 (10.1)
≥ 85 years	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Unknown	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
ECOG status at baseline ^a - n (%)					
0	2 (33.3)	6 (22.2)	1 (9.1)	26 (30.6)	35 (27.1)
1	3 (50.0)	21 (77.8)	9 (81.8)	54 (63.5)	87 (67.4)
≥ 2	1 (16.7)	0 (0.0)	1 (9.1)	5 (5.9)	7 (5.4)
Weight (kg)					
n	6	27	11	85	129
Mean	79.3	71.6	72.9	73.4	73.2
SD	23.4	17.4	20.4	21.3	20.4
Median	77.8	68.7	72.8	68.0	68.7
Q1, Q3	58.2, 99.9	60.5, 75.3	56.7, 86.0	57.7, 85.2	58.2, 84.4
Min, Max	57, 105	52, 133	42, 107	38, 146	38, 146
Height (cm)					
n	6	27	11	82	126
Mean	168.6	165.5	168.8	168.5	167.9
SD	14.5	7.2	11.1	9.7	9.6
Median	169.6	166.0	166.8	167.6	167.0
Q1, Q3	158.0, 180.3	160.0, 171.4	161.0, 181.2	162.0, 176.0	161.0, 175.3
Min, Max	147, 187	150, 180	152, 186	151, 189	147, 189
Prior line of anti-cancer therapy - n (%)					

	Phase 1 Any tumor 180 mg QD Fasted (N = 6)	Phase 1 Any tumor 360 mg QD Fasted (N = 27)	Phase 1 Any tumor 720 mg QD Fasted (N = 11)	Phase 1 Any tumor 960 mg QD Fasted (N = 85)	Phase 1 Any tumor Mono Total (N = 129)
0	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	0 (0.0)
1	0 (0.0)	1 (3.7)	1 (9.1)	15 (17.6)	17 (13.2)
2	2 (33.3)	5 (18.5)	1 (9.1)	24 (28.2)	32 (24.8)
3	2 (33.3)	4 (14.8)	4 (36.4)	15 (17.6)	25 (19.4)
> 3	2 (33.3)	17 (63.0)	5 (45.5)	29 (34.1)	53 (41.1)
Number of prior lines of therapy					
n	6	27	11	85	129
Mean	3.3	3.8	4.8	2.9	3.4
SD	1.4	1.4	3.1	1.7	2.0
Median	3.0	4.0	3.0	3.0	3.0
Q1, Q3	2.3, 4.5	3.0, 5.0	3.0, 8.0	2.0, 4.0	2.0, 4.0
Min, Max	2.0, 5.0	1.0, 6.0	1.0, 11.0	0, 10.0	0.0, 11.0

Table S2. Full List of Treatment-Emergent Adverse Events by Preferred Term

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Number of subjects reporting treatment-emergent adverse events	6 (100.0)	26 (96.3)	11 (100.0)	82 (96.5)	125 (96.9)
Diarrhoea	2 (33.3)	11 (40.7)	4 (36.4)	21 (24.7)	38 (29.5)
Fatigue	4 (66.7)	7 (25.9)	1 (9.1)	18 (21.2)	30 (23.3)
Nausea	2 (33.3)	7 (25.9)	2 (18.2)	16 (18.8)	27 (20.9)
Vomiting	0 (0.0)	4 (14.8)	1 (9.1)	18 (21.2)	23 (17.8)
Abdominal pain	2 (33.3)	4 (14.8)	2 (18.2)	15 (17.6)	23 (17.8)
Dyspnoea	2 (33.3)	4 (14.8)	4 (36.4)	11 (12.9)	21 (16.3)
Cough	2 (33.3)	3 (11.1)	2 (18.2)	13 (15.3)	20 (15.5)
Back pain	2 (33.3)	6 (22.2)	0 (0.0)	11 (12.9)	19 (14.7)
Decreased appetite	4 (66.7)	5 (18.5)	2 (18.2)	8 (9.4)	19 (14.7)
Headache	1 (16.7)	5 (18.5)	2 (18.2)	10 (11.8)	18 (14.0)
Aspartate aminotransferase increased	1 (16.7)	4 (14.8)	0 (0.0)	12 (14.1)	17 (13.2)
Anaemia	1 (16.7)	3 (11.1)	2 (18.2)	11 (12.9)	17 (13.2)
Dizziness	0 (0.0)	6 (22.2)	3 (27.3)	8 (9.4)	17 (13.2)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Alanine aminotransferase increased	1 (16.7)	3 (11.1)	0 (0.0)	11 (12.9)	15 (11.6)
Constipation	0 (0.0)	1 (3.7)	7 (63.6)	7 (8.2)	15 (11.6)
Pyrexia	1 (16.7)	3 (11.1)	0 (0.0)	10 (11.8)	14 (10.9)
Insomnia	0 (0.0)	2 (7.4)	4 (36.4)	8 (9.4)	14 (10.9)
Myalgia	0 (0.0)	4 (14.8)	0 (0.0)	9 (10.6)	13 (10.1)
Oedema peripheral	1 (16.7)	3 (11.1)	0 (0.0)	9 (10.6)	13 (10.1)
Arthralgia	1 (16.7)	6 (22.2)	1 (9.1)	5 (5.9)	13 (10.1)
Pneumonia	0 (0.0)	2 (7.4)	1 (9.1)	8 (9.4)	11 (8.5)
Upper respiratory tract infection	2 (33.3)	3 (11.1)	1 (9.1)	4 (4.7)	10 (7.8)
Pain in extremity	1 (16.7)	2 (7.4)	1 (9.1)	5 (5.9)	9 (7.0)
Productive cough	0 (0.0)	2 (7.4)	1 (9.1)	5 (5.9)	8 (6.2)
Blood alkaline phosphatase increased	1 (16.7)	2 (7.4)	0 (0.0)	5 (5.9)	8 (6.2)
Pleural effusion	0 (0.0)	0 (0.0)	2 (18.2)	5 (5.9)	7 (5.4)
Pruritus	1 (16.7)	1 (3.7)	0 (0.0)	5 (5.9)	7 (5.4)
Abdominal distension	1 (16.7)	3 (11.1)	1 (9.1)	2 (2.4)	7 (5.4)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Musculoskeletal pain	2 (33.3)	0 (0.0)	1 (9.1)	3 (3.5)	6 (4.7)
Urinary tract infection	0 (0.0)	2 (7.4)	2 (18.2)	2 (2.4)	6 (4.7)
Abdominal pain upper	1 (16.7)	2 (7.4)	1 (9.1)	2 (2.4)	6 (4.7)
Hot flush	1 (16.7)	4 (14.8)	0 (0.0)	1 (1.2)	6 (4.7)
Anxiety	0 (0.0)	0 (0.0)	0 (0.0)	5 (5.9)	5 (3.9)
Rash maculo-papular	0 (0.0)	0 (0.0)	0 (0.0)	5 (5.9)	5 (3.9)
Deep vein thrombosis	0 (0.0)	0 (0.0)	1 (9.1)	4 (4.7)	5 (3.9)
Gastroesophageal reflux disease	0 (0.0)	1 (3.7)	0 (0.0)	4 (4.7)	5 (3.9)
Pain	0 (0.0)	1 (3.7)	0 (0.0)	4 (4.7)	5 (3.9)
Small intestinal obstruction	0 (0.0)	1 (3.7)	0 (0.0)	4 (4.7)	5 (3.9)
Dehydration	1 (16.7)	0 (0.0)	0 (0.0)	4 (4.7)	5 (3.9)
Lung cancer metastatic	0 (0.0)	0 (0.0)	2 (18.2)	3 (3.5)	5 (3.9)
Peripheral sensory neuropathy	0 (0.0)	2 (7.4)	0 (0.0)	3 (3.5)	5 (3.9)
Non-cardiac chest pain	1 (16.7)	1 (3.7)	0 (0.0)	3 (3.5)	5 (3.9)
Neuropathy peripheral	0 (0.0)	3 (11.1)	0 (0.0)	2 (2.4)	5 (3.9)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Blood creatine phosphokinase increased	0 (0.0)	3 (11.1)	1 (9.1)	1 (1.2)	5 (3.9)
Influenza like illness	0 (0.0)	0 (0.0)	1 (9.1)	3 (3.5)	4 (3.1)
Hypertension	0 (0.0)	1 (3.7)	0 (0.0)	3 (3.5)	4 (3.1)
Dyspepsia	1 (16.7)	0 (0.0)	0 (0.0)	3 (3.5)	4 (3.1)
Hyperkalaemia	1 (16.7)	0 (0.0)	0 (0.0)	3 (3.5)	4 (3.1)
Hypophosphataemia	0 (0.0)	2 (7.4)	0 (0.0)	2 (2.4)	4 (3.1)
Nasopharyngitis	0 (0.0)	2 (7.4)	0 (0.0)	2 (2.4)	4 (3.1)
Chest pain	1 (16.7)	1 (3.7)	0 (0.0)	2 (2.4)	4 (3.1)
Dysphagia	1 (16.7)	1 (3.7)	0 (0.0)	2 (2.4)	4 (3.1)
Weight decreased	1 (16.7)	1 (3.7)	0 (0.0)	2 (2.4)	4 (3.1)
Musculoskeletal chest pain	0 (0.0)	1 (3.7)	2 (18.2)	1 (1.2)	4 (3.1)
Stomatitis	0 (0.0)	2 (7.4)	1 (9.1)	1 (1.2)	4 (3.1)
Contusion	1 (16.7)	1 (3.7)	2 (18.2)	0 (0.0)	4 (3.1)
Blood bilirubin increased	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.5)	3 (2.3)
Fall	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.5)	3 (2.3)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Pancreatic carcinoma	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.5)	3 (2.3)
Sepsis	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.5)	3 (2.3)
Sinus tachycardia	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.5)	3 (2.3)
Hyponatraemia	0 (0.0)	0 (0.0)	1 (9.1)	2 (2.4)	3 (2.3)
Asthenia	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Chills	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Gamma-glutamyltransferase increased	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Hypokalaemia	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Nasal congestion	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Oral candidiasis	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Weight increased	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Rash	1 (16.7)	0 (0.0)	0 (0.0)	2 (2.4)	3 (2.3)
Depression	0 (0.0)	0 (0.0)	2 (18.2)	1 (1.2)	3 (2.3)
Flank pain	0 (0.0)	0 (0.0)	2 (18.2)	1 (1.2)	3 (2.3)
Dry mouth	1 (16.7)	0 (0.0)	1 (9.1)	1 (1.2)	3 (2.3)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Lymphocyte count decreased	1 (16.7)	0 (0.0)	1 (9.1)	1 (1.2)	3 (2.3)
Wheezing	1 (16.7)	0 (0.0)	1 (9.1)	1 (1.2)	3 (2.3)
Flatulence	0 (0.0)	2 (7.4)	0 (0.0)	1 (1.2)	3 (2.3)
Malaise	0 (0.0)	2 (7.4)	0 (0.0)	1 (1.2)	3 (2.3)
Muscular weakness	0 (0.0)	2 (7.4)	0 (0.0)	1 (1.2)	3 (2.3)
Oropharyngeal pain	0 (0.0)	2 (7.4)	0 (0.0)	1 (1.2)	3 (2.3)
Hypercalcaemia	1 (16.7)	1 (3.7)	0 (0.0)	1 (1.2)	3 (2.3)
Hallucination	0 (0.0)	1 (3.7)	2 (18.2)	0 (0.0)	3 (2.3)
Colorectal cancer metastatic	0 (0.0)	2 (7.4)	1 (9.1)	0 (0.0)	3 (2.3)
Dysuria	0 (0.0)	2 (7.4)	1 (9.1)	0 (0.0)	3 (2.3)
Anal fistula	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Ascites	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Blood creatinine increased	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Dermatitis acneiform	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Dysgeusia	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Hypomagnesaemia	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Hypoxia	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Leukopenia	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Pancreatic carcinoma metastatic	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Pollakiuria	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Respiratory failure	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Rhinorrhoea	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Seizure	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Upper-airway cough syndrome	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Urinary retention	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Abdominal pain lower	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)
Acute kidney injury	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)
Clostridium difficile infection	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)
Oral herpes	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)
Somnolence	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Bronchitis	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Embolism	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Fracture	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Hypocalcaemia	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Neck pain	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Night sweats	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Oral pain	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Pelvic pain	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Pericardial effusion	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Tachycardia	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Tumour pain	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Vertigo	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Haematuria	1 (16.7)	0 (0.0)	0 (0.0)	1 (1.2)	2 (1.6)
Sinusitis	1 (16.7)	0 (0.0)	0 (0.0)	1 (1.2)	2 (1.6)
White blood cell count decreased	1 (16.7)	0 (0.0)	0 (0.0)	1 (1.2)	2 (1.6)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Haemoptysis	0 (0.0)	0 (0.0)	2 (18.2)	0 (0.0)	2 (1.6)
Cognitive disorder	0 (0.0)	1 (3.7)	1 (9.1)	0 (0.0)	2 (1.6)
Dry skin	0 (0.0)	1 (3.7)	1 (9.1)	0 (0.0)	2 (1.6)
Influenza	0 (0.0)	1 (3.7)	1 (9.1)	0 (0.0)	2 (1.6)
Hypoaesthesia	0 (0.0)	2 (7.4)	0 (0.0)	0 (0.0)	2 (1.6)
Paraesthesia	1 (16.7)	1 (3.7)	0 (0.0)	0 (0.0)	2 (1.6)
Urinary incontinence	1 (16.7)	1 (3.7)	0 (0.0)	0 (0.0)	2 (1.6)
Abdominal hernia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Acute myocardial infarction	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Akathisia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Alopecia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Anal skin tags	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Anorectal discomfort	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Arthritis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Aspiration	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Atrial fibrillation	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Bacterial infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Bladder irritation	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Bladder outlet obstruction	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Blood lactate dehydrogenase increased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Bone pain	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Bradycardia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Brain injury	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Breast haematoma	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Cancer pain	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Cardiac arrest	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Cellulitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Central nervous system necrosis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Cervical radiculopathy	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Cholangiocarcinoma	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Diarrhoea haemorrhagic	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Dry eye	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Duodenal obstruction	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Dyslipidaemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Dyspnoea exertional	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Ear pain	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Epistaxis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Facial pain	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Fractured sacrum	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Haematoma	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Haematoma muscle	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Haemorrhage intracranial	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Hepatitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Hepatomegaly	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Hiccups	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Hyperglycaemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Hypertriglyceridaemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Hypoglycaemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Hypotension	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Injection site bruising	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Injection site haematoma	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Jaundice	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Jaw fracture	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Large intestinal obstruction	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Liver function test abnormal	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Malignant pleural effusion	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Mental status changes	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Mitochondrial aspartate aminotransferase increased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Mouth ulceration	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Muscle spasms	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Muscle strength abnormal	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Myocardial infarction	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Neutrophil count decreased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Oedema	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Oesophageal motility disorder	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Orthostatic hypotension	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Osteoarthritis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Pathological fracture	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Peripheral swelling	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Post procedural infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Procedural pneumothorax	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Pruritus allergic	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Pseudohyperkalaemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Pulmonary embolism	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Radiation proctitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Rash erythematous	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Rash pustular	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Restless legs syndrome	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Rhinitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Scrotal oedema	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Seasonal allergy	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Seborrhoeic keratosis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Secretion discharge	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Sinus operation	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Skin lesion	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Spinal compression fracture	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Spondylolisthesis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Stent malfunction	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Tendon disorder	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Thrombocytopenia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Tooth infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Transaminases increased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Urinary tract infection bacterial	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Urinary tract infection enterococcal	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Urinary tract infection pseudomonal	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Urinary tract obstruction	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Vaginal infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Vulvovaginal pain	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Wound	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Adrenal haemorrhage	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Atrophic vulvovaginitis	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Behaviour disorder	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Brain oedema	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Burning sensation	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Creatinine renal clearance increased	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Delirium	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Delusion	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Hyperplastic cholecystopathy	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Ileus	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Incontinence	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Irritability	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Lacrimation increased	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Lip dry	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Lower respiratory tract infection	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Mesenteric vein thrombosis	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Migraine	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Musculoskeletal disorder	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Oesophagitis	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Sinus congestion	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Tremor	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Vision blurred	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Adult failure to thrive	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Alanine aminotransferase	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Aspartate aminotransferase	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Atelectasis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Biliary tract infection	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
C-reactive protein increased	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Cholecystitis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Cystitis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Eructation	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Failure to thrive	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Fungal oesophagitis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Gynaecomastia	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Hyperaesthesia	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Hyperfibrinogenaemia	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Hyperhidrosis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Hyperleukocytosis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Hypersensitivity	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Ligament sprain	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Lung adenocarcinoma	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Macrocytosis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Malignant biliary obstruction	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Metabolic encephalopathy	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Muscle twitching	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Myopathy	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Nodule	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Non-small cell lung cancer	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Non-small cell lung cancer metastatic	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Occipital neuralgia	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Palpitations	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)

Preferred Term	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Pneumothorax	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Polycythaemia	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Post procedural haemorrhage	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Pulmonary haemorrhage	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Sciatica	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Skin swelling	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Swelling face	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Urinary hesitation	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Vitreous floaters	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Cheilitis	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Herpes zoster	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Joint range of motion decreased	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Neuralgia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Proteinuria	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Respiratory tract infection	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)

Table S3. Full List of Treatment-Related Adverse Events by System Organ Class, Preferred Term, and Grade

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Number of subjects reporting treatment-emergent treatment-related adverse events	2 (33.3)	19 (70.4)	9 (81.8)	43 (50.6)	73 (56.6)
Any system organ class	2 (33.3)	19 (70.4)	9 (81.8)	43 (50.6)	73 (56.6)
Any Preferred term	2 (33.3)	19 (70.4)	9 (81.8)	43 (50.6)	73 (56.6)
Grade ≥ 2	2 (33.3)	10 (37.0)	5 (45.5)	24 (28.2)	41 (31.8)
Grade ≥ 3	0 (0.0)	4 (14.8)	2 (18.2)	9 (10.6)	15 (11.6)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Blood and lymphatic system disorders	0 (0.0)	1 (3.7)	2 (18.2)	6 (7.1)	9 (7.0)
Anaemia	0 (0.0)	1 (3.7)	2 (18.2)	5 (5.9)	8 (6.2)
Grade ≥ 2	0 (0.0)	1 (3.7)	2 (18.2)	4 (4.7)	7 (5.4)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 3	0 (0.0)	0 (0.0)	2 (18.2)	2 (2.4)	4 (3.1)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leukopenia	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Eye disorders	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Lacrimation increased	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Gastrointestinal disorders	2 (33.3)	9 (33.3)	6 (54.5)	21 (24.7)	38 (29.5)
Diarrhoea	1 (16.7)	6 (22.2)	4 (36.4)	15 (17.6)	26 (20.2)
Grade ≥ 2	0 (0.0)	4 (14.8)	2 (18.2)	6 (7.1)	12 (9.3)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 3	0 (0.0)	3 (11.1)	0 (0.0)	2 (2.4)	5 (3.9)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Nausea	0 (0.0)	3 (11.1)	1 (9.1)	4 (4.7)	8 (6.2)
Grade ≥ 2	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Abdominal pain	0 (0.0)	0 (0.0)	1 (9.1)	5 (5.9)	6 (4.7)
Grade ≥ 2	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Vomiting	0 (0.0)	1 (3.7)	1 (9.1)	4 (4.7)	6 (4.7)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Abdominal distension	0 (0.0)	1 (3.7)	1 (9.1)	1 (1.2)	3 (2.3)
Grade ≥ 2	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dry mouth	1 (16.7)	0 (0.0)	1 (9.1)	1 (1.2)	3 (2.3)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Gastroesophageal reflux disease	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Stomatitis	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Diarrhoea haemorrhagic	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 2	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Eructation	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Flatulence	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Cheilitis	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
General disorders and administration site conditions	0 (0.0)	5 (18.5)	0 (0.0)	10 (11.8)	15 (11.6)
Fatigue	0 (0.0)	4 (14.8)	0 (0.0)	7 (8.2)	11 (8.5)
Grade ≥ 2	0 (0.0)	2 (7.4)	0 (0.0)	3 (3.5)	5 (3.9)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Oedema peripheral	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asthenia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pyrexia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hepatobiliary disorders	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Hepatitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Infections and infestations	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Rash pustular	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Oral candidiasis	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Injury, poisoning and procedural complications	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Contusion	0 (0.0)	0 (0.0)	1 (9.1)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Investigations	1 (16.7)	5 (18.5)	1 (9.1)	15 (17.6)	22 (17.1)
Aspartate aminotransferase increased	1 (16.7)	2 (7.4)	0 (0.0)	11 (12.9)	14 (10.9)
Grade ≥ 2	0 (0.0)	2 (7.4)	0 (0.0)	8 (9.4)	10 (7.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.5)	3 (2.3)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Alanine aminotransferase increased	1 (16.7)	2 (7.4)	0 (0.0)	10 (11.8)	13 (10.1)
Grade ≥ 2	0 (0.0)	2 (7.4)	0 (0.0)	8 (9.4)	10 (7.8)
Grade ≥ 3	0 (0.0)	1 (3.7)	0 (0.0)	5 (5.9)	6 (4.7)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Blood alkaline phosphatase increased	1 (16.7)	2 (7.4)	0 (0.0)	4 (4.7)	7 (5.4)
Grade ≥ 2	0 (0.0)	2 (7.4)	0 (0.0)	3 (3.5)	5 (3.9)
Grade ≥ 3	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Blood creatine phosphokinase increased	0 (0.0)	2 (7.4)	0 (0.0)	1 (1.2)	3 (2.3)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Blood bilirubin increased	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lymphocyte count decreased	0 (0.0)	0 (0.0)	1 (9.1)	1 (1.2)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
White blood cell count decreased	1 (16.7)	0 (0.0)	0 (0.0)	1 (1.2)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Blood creatinine increased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Liver function test abnormal	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Mitochondrial aspartate aminotransferase increased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neutrophil count decreased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Transaminases increased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Weight decreased	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Alanine aminotransferase	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Aspartate aminotransferase	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Gamma-glutamyltransferase increased	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Metabolism and nutrition disorders	1 (16.7)	4 (14.8)	1 (9.1)	5 (5.9)	11 (8.5)
Decreased appetite	0 (0.0)	3 (11.1)	1 (9.1)	2 (2.4)	6 (4.7)
Grade ≥ 2	0 (0.0)	2 (7.4)	1 (9.1)	1 (1.2)	4 (3.1)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypophosphataemia	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Grade ≥ 2	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypomagnesaemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hyponatraemia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Hyperkalaemia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Musculoskeletal and connective tissue disorders	0 (0.0)	2 (7.4)	0 (0.0)	5 (5.9)	7 (5.4)
Myalgia	0 (0.0)	1 (3.7)	0 (0.0)	2 (2.4)	3 (2.3)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Arthralgia	0 (0.0)	1 (3.7)	0 (0.0)	1 (1.2)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Arthritis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Muscle spasms	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Seborrhoeic keratosis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Nervous system disorders	0 (0.0)	1 (3.7)	0 (0.0)	3 (3.5)	4 (3.1)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Neuropathy peripheral	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dysgeusia	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Peripheral sensory neuropathy	0 (0.0)	1 (3.7)	0 (0.0)	0 (0.0)	1 (0.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Renal and urinary disorders	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Proteinuria	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Epistaxis	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Nasal congestion	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Skin and subcutaneous tissue disorders	0 (0.0)	0 (0.0)	0 (0.0)	6 (7.1)	6 (4.7)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Pruritus	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.5)	3 (2.3)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Rash	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.4)	2 (1.6)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Rash erythematous	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Rash maculo-papular	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Vascular disorders	1 (16.7)	0 (0.0)	0 (0.0)	1 (1.2)	2 (1.6)
Hypertension	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)	1 (0.8)

System Organ Class Preferred Term Grade	Phase 1 Any tumor 180 mg QD Fasted (N = 6) n (%)	Phase 1 Any tumor 360 mg QD Fasted (N = 27) n (%)	Phase 1 Any tumor 720 mg QD Fasted (N = 11) n (%)	Phase 1 Any tumor 960 mg QD Fasted (N = 85) n (%)	Phase 1 Any tumor Mono Total (N = 129) n (%)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hot flush	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.8)
Grade ≥ 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Grade ≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatal	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Supplementary Figures

Figure S1. Co-crystal Structure of GDP-KRAS^{G12C} Bound by Sotorasib

Co-crystal structure of sotorasib bound to GDP-KRAS^{G12C}, confirming covalent bond formation between the acrylamide warhead and C12 and illustrating non-covalent contacts between the isopropylpyridine substituent and the H95/Y96/Q99 cryptic pocket. H95 denotes amino acid of histidine at position 95 of KRAS^{G12C}. Y96 denotes amino acid of tyrosine at position 96 of KRAS^{G12C}. Q99 denotes amino acid of glutamine at position 99 of KRAS^{G12C}. C12 denotes mutated cysteine at position 12.




Figure S2. Patient Disposition

Diagram shows patient enrollment, dosing schedules, and treatment status at data cutoff




Figure S3. Pharmacokinetics of Sotorasib

PK data cutoff was July 24, 2019. Data from 32 patients were used. Only the top error bars are shown for clarity on a semi-logarithmic scale (non-symmetric scale).




Figure S4. CT Scans of Two Patients With NSCLC

Figure S4 shows CT scans from baseline and subsequent follow-ups for two patients with NSCLC. Both patients achieved PR.






Figure S5. Efficacy of Sotorasib in Patients With Colorectal Cancer

Panel A shows best percent change in tumor burden in patients with colorectal cancer whose postbaseline tumor data are available. Panel B shows time to response, treatment over time, and treatment status at data cutoff for all patients with colorectal cancer. Panel C shows tumor burden change over time in patients with colorectal cancer whose postbaseline tumor data are available. Panel D shows Kaplan-Meier curve of progression-free survival in all patients with colorectal cancer.


A. Best percent change in tumor burden among patients with colorectal cancer receiving sotorasib



B. Tumor response and treatment over time in patients with colorectal cancer



C. Change in tumor burden from baseline over time in patients with colorectal cancer



D. Progression-free survival in patients with colorectal cancer





Figure S6. Efficacy of Sotorasib in Patients With Other Tumor Types

Panel A shows best percent change in tumor burden in patients with other tumor types whose postbaseline tumor data are available. Panel B shows time to response, treatment over time, and treatment status at data cutoff for all 28 patients with other tumor types.

A. Best percent change in tumor burden among patients with other tumor types receiving sotorasib



B. Tumor response and treatment over time in patients with other tumor types

